Literature DB >> 21743977

Colorectal liver metastasis in the setting of lymph node metastasis: defining the benefit of surgical resection.

Carlo Pulitanò1, Martin Bodingbauer, Luca Aldrighetti, Michael A Choti, Federico Castillo, Richard D Schulick, Thomas Gruenberger, Timothy M Pawlik.   

Abstract

BACKGROUND: For patients with colorectal liver metastasis (CLM), the presence of concomitant perihepatic/para-aortic lymph node metastasis (LNM) is considered a contraindication to liver resection. We sought to determine the benefits of liver resection among patients with CLM + LNM by examining long-term outcomes among a large cohort of patients.
METHODS: Between October 1996 and December 2007, 61 patients with CLM and pathologically proven LNM were identified from an international multi-institutional database of 1629 patients. The effect of LNM, as well as other prognostic factors, on recurrence-free and overall survival was analyzed.
RESULTS: Median overall survival was 32 months, and 1-, 3-, and 5-year overall survival were 86, 35, and 18%, respectively. Five patients were alive and disease-free at last follow-up. Survival was associated with location of LNM. Specifically, 5-year overall survival was 30% among patients with LNM along the hepatoduodenal ligament/retropancreatic area (area 1), 14% among patients with LNM along the common hepatic artery/celiac axis (area 2), and there was only one long-term survivor who experienced recurrent disease among patients who had CLM + para-aortic LNM (area 3) (P = 0.004). On multivariate analyses, overall margin status (hazard ratio [HR] = 2.0), treated number of metastases >6 (HR = 2.3) and para-aortic lymph node involvement (HR = 2.6) each remained significantly associated with increased risk of death (all P < 0.05).
CONCLUSIONS: Although overall survival in the setting of LNM is only 18%, certain subsets of patients with LNM can benefit from surgical resection. Specifically, patients with CLM + LNM isolated to area 1 had a 5-year survival of approximately 30%, while long-term survival among patients with para-aortic LNM was rare.

Entities:  

Mesh:

Year:  2011        PMID: 21743977     DOI: 10.1245/s10434-011-1902-1

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  15 in total

Review 1.  Lymphatics and colorectal liver metastases: the case for sentinel node mapping.

Authors:  Christopher Christophi; Linh Nguyen; Vijayaragavan Muralidharan; Mehrdad Nikfarjam; Jonathan Banting
Journal:  HPB (Oxford)       Date:  2013-07-19       Impact factor: 3.647

2.  Percutaneous ablation of lymph node metastases using CT-guided high-dose-rate brachytherapy.

Authors:  F Collettini; A C Schippers; D Schnapauff; T Denecke; B Hamm; H Riess; P Wust; B Gebauer
Journal:  Br J Radiol       Date:  2013-05-09       Impact factor: 3.039

3.  Resection of non-hepatic colorectal cancer metastasis.

Authors:  Fabian M Johnston; Peter J Kneuertz; Timothy M Pawlik
Journal:  J Gastrointest Oncol       Date:  2012-03

Review 4.  Colorectal cancer with liver metastases: neoadjuvant chemotherapy, surgical resection first or palliation alone?

Authors:  Khurum Khan; Anita Wale; Gina Brown; Ian Chau
Journal:  World J Gastroenterol       Date:  2014-09-21       Impact factor: 5.742

5.  Colorectal Cancer Liver Metastases and Concurrent Extrahepatic Disease Treated With Resection.

Authors:  Universe Leung; Mithat Gönen; Peter J Allen; T Peter Kingham; Ronald P DeMatteo; William R Jarnagin; Michael I D'Angelica
Journal:  Ann Surg       Date:  2017-01       Impact factor: 12.969

Review 6.  Resection of colorectal liver metastases and extra-hepatic disease: a systematic review and proportional meta-analysis of survival outcomes.

Authors:  William J Hadden; Philip R de Reuver; Kai Brown; Anubhav Mittal; Jaswinder S Samra; Thomas J Hugh
Journal:  HPB (Oxford)       Date:  2016-02-01       Impact factor: 3.647

7.  Impact of hepatic lymph node metastasis on survival of patients with synchronous resectable or unresectable liver metastases of colorectal cancer.

Authors:  K Ishibashi; H Ishida; T Ohsawa; N Okada; K Kumamoto; N Haga
Journal:  Tech Coloproctol       Date:  2012-08-31       Impact factor: 3.781

8.  Parenchyma-preserving hepatic resection for colorectal liver metastases.

Authors:  Maximilian von Heesen; Jochen Schuld; Jens Sperling; Frank Grünhage; Frank Lammert; Sven Richter; Martin K Schilling; Otto Kollmar
Journal:  Langenbecks Arch Surg       Date:  2011-11-17       Impact factor: 3.445

9.  Prognostic impact of perihepatic lymph node metastases in patients with resectable colorectal liver metastases.

Authors:  M Okuno; C Goumard; T Mizuno; S Kopetz; K Omichi; C-W D Tzeng; Y S Chun; J E Lee; J-N Vauthey; C Conrad
Journal:  Br J Surg       Date:  2018-04-17       Impact factor: 6.939

10.  Successful resection of metachronous para-aortic, Virchow lymph node and liver metastatic recurrence of rectal cancer.

Authors:  Nobuyoshi Takeshita; Toru Fukunaga; Masayuki Kimura; Yuji Sugamoto; Kentaro Tasaki; Isamu Hoshino; Takumi Ota; Tetsuro Maruyama; Tomohide Tamachi; Takashi Hosokawa; Yo Asai; Hisahiro Matsubara
Journal:  World J Gastroenterol       Date:  2015-11-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.